NCT05442983已完成2 期
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 75
- 试验地点
- 1
- 主要终点
- Time to Viral Clearance
研究概览
简要总结
This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-hospitalized Patients with RT-PCR confirmed COVID-19 in ≤ 48 hours prior to randomization.
- •Patients with WHO Ordinal Scale score 1 and
- •Patient has presented within 5 days or less of randomization with at least one early onset COVID-19 symptom (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, vomiting or diarrhea).
- •Men and non-pregnant women, 18 - 65 years of age.
- •Patient has estimated glomerular filtration rate (eGFR) ≥30 mL/min using the Cockcroft-Gault formula.
- •Willing to participate in this study, signed Informed Consent and willing to participate in regular follow-up during the study.
- •Able to understand and cooperate with study procedures. -
排除标准
- •Subjects hospitalized (a) Patients with severe or critical forms of COVID-19 illness or those who are on ventilator support, ECMO, or shock requiring vasopressor support or those with cytokine storm; even not in hospital (b) Patients hospitalized for treatment of severe illnesses (c) "Long COVID-19" syndrome (defined as a diverse set of symptoms that persist after a minimum of 4 weeks from the onset of a diagnosed COVID-19 infection. Common symptoms include respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain, and anemia).
- •Patients with known blood dyscrasia and uric acid kidney stones.
- •Females who are pregnant, breast feeding, or planning a pregnancy.
- •Females of childbearing potential who do not agree to utilize an adequate effective form of contraception.
- •Males with partners of child-bearing potential unwilling to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence effective from the first administration of any of the IPs throughout the trial.
- •Men with partners of child-bearing potential unwilling to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel, or sexual abstinence. Men with pregnant or lactating partners unwilling to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the fetus or neonate.
- •Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the patients. Periodic abstinence (e.g., calendar, ovulation, sympathothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- •History of alcohol, chemical, or drug abuse or dependence as per DSM IV criteria within past 6 months.
- •Current active malignancy or history of malignancy within the past five years.
- •Known hypersensitivity history to Investigational Products or any of its component.
- •Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.
- •Patients with the following conditions:
- •Immunosuppression
- •Current neoplasms
- •Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma.
- •Any other clinically significant abnormal medical condition, which in the Investigator's judgment, would put the patient at increased risk of illness or injury would interfere with study participation or would interfere with the evaluation or quality of the data.
- •Investigator's judgment that participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.
- •Is taking or is anticipated to require any prohibited medications or therapies.
- •Participation in another trial within previous 3 months and is unwilling to abstain from participating in another interventional clinical study through Day 28 with an investigational compound or device, including those for COVID-19 therapeutics.
- •Any patient that is already taking Investigational Medicinal Products. -
研究组 & 干预措施
PanCytoVir™ 500 mg twice daily
Experimental
干预措施: PanCytoVir™ (probenecid) (Drug)
PanCytoVir™ 1000 mg twice daily
Experimental
干预措施: PanCytoVir™ (probenecid) (Drug)
Placebo twice daily
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Time to Viral Clearance
时间窗: 5 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 PeopleCOVID-19NCT05667714Sinovac Life Sciences Co., Ltd.2,900
招募中
不适用
Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and OverSARS-CoV-2NCT05745545AIM Vaccine Co., Ltd.3,200
已完成
1 期
Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected AdultsHIV-1 InfectionsNCT01151319University of Oxford32
已完成
1 期
A Study of RO6799477 in Healthy VolunteersHealthy VolunteerNCT01893437Hoffmann-La Roche27
已完成
4 期
PDEI Following Mitral Valve Surgery in Patients With Pulmonary HypertensionMitral Valve SurgeryPulmonary HypertensionNCT02378649Dr. Robert Klempfner Heart Rehabilitation Institute60